Researchers developed a novel electrochemical biosensor technology capable of assessing symmetric dimethylarginine to detect early kidney disease, which could be adapted to detect other biomarkers for ...

Medtronic plc and Tempus AI Inc. launched the ALERT study to better understand and address the racial, ethnic, gender and ...

Transposon Therapeutics Inc. has acquired a portfolio of novel nucleoside analogues from Primefour Therapeutics Inc. for the targeted treatment of pancreatic cancer, certain other solid tumors and ...

Urocortin-2 (UCN2) is a selective corticotropin-releasing factor CRF2 receptor (CRFR2) agonist, which has been previously shown to reduce fat mass while promoting muscle hypertrophy. Hanmi ...

Chiome Bioscience Inc. and Asahi Kasei Pharma Corp. have entered into an exclusive license agreement to develop and commercialize Chiome’s humanized anti-CX3CR1 antibody, PFKR, currently in the ...

Enanta Pharmaceuticals Inc. has released preclinical pharmacokinetics (PK) data for EDP-514, a potent and selective class II core assembly modulator in phase I development for the oral treatment of ...

Nine out of 10 people with chronic kidney disease have no idea their kidneys are impaired, largely because of a lack of routine testing for albuminuria, one of the earliest biomarker for the disease.

Former U.S. FDA Commissioner Margaret Hamburg has added her voice to concerns that the incoming Trump administration’s pledge to slim down federal agencies will damage public health. “These are ...

Telomir Pharmaceuticals Inc. has reported preclinical results from evaluation of Telomir-1 in Caenorhabditis elegans, a well-established model for aging studies. Telomir-1 is a novel small molecule ...

Startup company Pep2tango Therapeutics Inc., unveiled with backing by Versant Ventures, is advancing unimolecular multireceptor peptide agonists that target GLP-1, GIP, amylin and calcitonin receptors ...

Autoimmunity Biosolutions has closed a seed financing to support its work advancing a next-generation, immuno-corrective therapy for autoimmune diseases. The company’s approach targets a branch of the ...

The U.S. FDA approved 15 drugs in October, marking a decline from 24 in September and 22 in August. Despite the drop, the 2024 monthly average stands at about 19 approvals, exceeding last year’s ...